Expert Discusses Recent CLL Approval

Video

The recent approval of ibrutinib plus obinutuzumab is a major advancement in the chronic lymphocytic leukemia space.

Suman Kambhampati, MD, the co-director of blood cancer research at Sarah Cannon Cancer Institute at HCA Midwest Health, discusses the recent FDA approval of ibrutinib (Imbruvica) plus obinutuzumab (Gazyva) for the frontline treatment of patients with chronic lymphocytic leukemia (CLL).

The approval was based on the phase III iLLUMINATE trial, which showed that ibrutinib plus obinutuzumab was the first non-chemotherapy combination that was extremely effective in treating nearly all subtypes of patients with CLL. The combination elicited a longer progression-free survival (PFS), nearly a 100% response rate, and better complete responses (CR) than treatment with ibrutinib alone, making it an extremely exciting treatment option for these patients.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Photo of a man with a beard in front of a blue background
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Image of a woman with light brown hair wearing glasses with a blue background
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background
Related Content